Investigating AntiDFS70 in Lupus Nephritis
Anti-DFS70 Antibodies and it's Relationship With Systemic Lupus Erythematosus Manifestations
This study is trying to see how anti-DFS70 antibodies affect people with lupus nephritis to help understand their role in the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Trial ID | NCT06119763 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients diagnosed with systemic lupus erythematosus (SLE), a complex autoimmune disease that can affect various organs. It aims to explore the role of anti-DFS70 antibodies and their clinical implications in SLE, particularly in relation to lupus nephritis. The study will include patients who meet specific classification criteria for SLE and are able to provide informed consent. By analyzing the presence of anti-DFS70 antibodies, the study seeks to better understand their significance in the disease's progression and management.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals who meet the classification criteria for systemic lupus erythematosus and can provide informed consent.
Not a fit: Patients with other collagen diseases besides systemic lupus erythematosus may not receive any benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of lupus nephritis and lead to improved diagnostic and treatment strategies for patients with systemic lupus erythematosus.
How similar studies have performed: While the role of anti-DFS70 antibodies in SLE is an emerging area of interest, this specific approach appears to be novel and not extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients who fulfill the 2019 American College of Rheumatology/European League against Rheumatism classification criteria of Systemic Lupus Erythematous . (9) 2. Patients who is able to give informed consent to join the study. • Exclusion Criteria: - - Any patient with any collagen disease other than systemic lupus erythematous
Where this trial is running
Sohag
- Sohag university Hospital — Sohag, Egypt (Recruiting)
Study contacts
- Study coordinator: ashrakat s Mohammed, resident
- Email: ashraketshaaban@med.sohag.edu.eg
- Phone: 01005046015
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.